Please join me in congratulating Karyopharm Therapeutics. Karyopharm Therapeutics, on July 3rd, 2019 was granted FDA approval for its Multiple Myeloma Drug, Xpovio. Dr. Raphael Nir helped foster and conduct early research stages through SBH Sciences drug optimization services. A huge accomplishment for Karyopharm Therapeutics for becoming the first and only prescription medicine approved by the FDA for the treatment of patients with multiple myeloma whose disease is refractory to proteasome inhibitors, immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Dr. Nir has incubated many other companies at ABI-LAB located in Natick Massachusetts. For more information on ABI-LAB or if you are interested in becoming part of our community, please email me or check out our website at ABI-LAB.com.